FARE Statement on FDA Warning Letter
FARE has issued the following statement following reports on CNBC about an FDA warning letter to Pfizer concerning epinephrine auto-injectors.
“The food allergy community relies on epinephrine auto-injector devices for quick, dependable administration of epinephrine, the only medication that can stop the symptoms of a severe reaction. The lives of children and adults with food allergies depend on them working precisely as they should, so anytime there are issues with an epinephrine auto-injector malfunctioning, we have serious concerns. At this time, we are waiting to learn more from the FDA and the manufacturer about the safety of these essential products.” - James R. Baker, Jr., MD, CEO and chief medical officer of Food Allergy Research & Education.
Media Contact:
About FARE
FARE (Food Allergy Research & Education) is the leading nonprofit organization that empowers the food allergy patient across the journey of managing their disease. FARE delivers innovation by focusing on three strategic pillars—advocacy, research, and education—united by the through line of health equity. FARE’s initiatives accelerate the future of food allergy through effective policies and legislation, novel strategies toward prevention, diagnosis, and treatment, and building awareness and community. For more information, visit FoodAllergy.org.